Expert review of anticancer therapy

How enzalutamide is used and why prostate cancer may resist it

Updated

Abstract

Enzalutamide is an effective prostate cancer therapy currently used for various tumor types, but resistance may develop in all cases.

  • Resistance to enzalutamide occurs in biochemically recurrent, metastatic, castration-sensitive, and castration-resistant tumors.
  • AR-driven resistance mechanisms involve genetic or epigenetic changes that enhance androgen receptor signaling.
  • Some tumors may not rely on androgen receptor signaling and could utilize alternative cancer pathways.
  • Strategies to counteract enzalutamide resistance include the concurrent use of PARP inhibitors or immune therapies.
  • Further research is needed to discover new treatment options for patients experiencing enzalutamide resistance.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

E.S. Antonarakis reports grants and personal fees from Janssen, Sanofi, Bayer, Bristol Myers Squibb, Curium, MacroGenics, Merck, Pfizer, AstraZeneca, and Clovis; personal fees from Aadi Bioscience, Aikido Pharma, Astellas, Amgen, Blue Earth, Corcept Therapeutics, Exact Sciences, Hookipa Pharma, Invitae, Eli Lilly, Foundation Medicine, Menarini-Silicon Biosystems, Tango Therapeutics, Tempus and Z-alpha; grants from Novartis, Celgene, and Orion; and has a patent for an AR-V7 biomarker technology that has been licensed to Qiagen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free